Multiparametric magnetic resonance imaging (mpMRI) provides enhanced diagnostic accuracy in the detection of prostate cancer, but is not devoid of limitations. Given the recent evolution of non-MRI imaging techniques, this critical review of the literature aimed at summarizing the available evidence on ultrasound-based and nuclear medicine imaging technologies in the initial diagnosis of PCa.
Three databases (PubMed®, Web of Science™, and Scopus®) were queried for studies examining their diagnostic performance in the primary diagnosis of PCa, weighted against a histological confirmation of PCa diagnosis, using a free-text protocol. Retrospective and prospective studies, both comparative and non-comparative, systematic reviews (SR) and meta-analysis (MA) were included. Based on authors’ expert opinion, studies were selected, data extracted, and results qualitatively described.
Micro-ultrasound (micro-US) appears as an appealing diagnostic strategy given its high accuracy in detection of PCa, apparently non-inferior to mpMRI. The use of multiparametric US (mpUS) likely gives an advantage in terms of effectiveness coming from the combination of different modalities, especially when certain modalities are combined. Prostate-specific membrane antigen (PSMA) PET/CT may represent a whole-body, one-step approach for appropriate diagnosis and staging of PCa. The direct relationship between lesions avidity of radiotracers and histopathologic and prognostic features, and its valid diagnostic performance represents appealing characteristics. However, intrinsic limits of each of these techniques exist and further research is needed before definitively considering them reliable tools for accurate PCa diagnosis. Other novel technologies, such as elastography and multiparametric US, currently relies on a limited number of studies, and therefore evidence about them remains preliminary.
Evidence on the role of non-MRI imaging options in the primary diagnosis of PCa is steadily building up. This testifies a growing interest towards novel technologies that might allow overcoming some of the limitations of current gold standard MRI imaging.
This is a preview of subscription content, access via your institution
Subscribe to this journal
Receive 4 print issues and online access
$259.00 per year
only $64.75 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
Rouvière O, Puech P, Renard-Penna R, Claudon M, Roy C, Mège-Lechevallier F, et al. Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study. Lancet Oncol. 2019;20:100–9.
Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH, et al. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. N Engl J Med. 2018;378:1767–77.
Wei JT, Barocas D, Carlsson S, Coakley F, Eggener S, Etzioni R, et al. Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening. J Urol [Internet]. 2023 Apr;101097JU0000000000003491. Available from: http://www.ncbi.nlm.nih.gov/pubmed/37096582
Mottet N, Cornford P, van den Bergh RCN, Briers E, Eberli D, De Meerleer G, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer 2023. Edn. presented at the EAU Annual Congress Milan 2023. ISBN 978-94-92671-19-6. [Internet]. [cited 2023 May 23]. Available from: https://uroweb.org/guidelines/prostate-cancer
Radtke JP, Teber D, Hohenfellner MR, Hadaschik BA. The current and future role of magnetic resonance imaging in prostate cancer detection and management. Transl Androl Urol. 2015;4:326–41.
Stabile A, Giganti F, Rosenkrantz AB, Taneja SS, Villeirs G, Gill IS, et al. Multiparametric MRI for prostate cancer diagnosis: current status and future directions. Nat Rev Urol Nat Res. 2020;17:41–61.
Santoro AA, Di Gianfrancesco L, Racioppi M, Pinto F, Palermo G, Sacco E, et al. Multiparametric magnetic resonance imaging of the prostate: Lights and shadows. Urologia J 2021;88:280–6.
Beerlage HP, Aarnink RG, Ruijter E, Witjes JA, Wijkstra H, Van De Kaa CA, et al. Correlation of transrectal ultrasound, computer analysis of transrectal ultrasound and histopathology of radical prostatectomy specimen. Prostate Cancer Prostatic Dis [Internet]. 2001;56–62. Available from: www.nature.com/pcan
Calace FP, Napolitano L, Arcaniolo D, Stizzo M, Barone B, Crocetto F, et al. Micro-Ultrasound in the Diagnosis and Staging of Prostate and Bladder Cancer: A Comprehensive Review. 58, Medicina (Lithuania). MDPI; 2022.
Correas JM, Halpern EJ, Barr RG, Ghai S, Walz J, Bodard S, et al. Advanced ultrasound in the diagnosis of prostate cancer. World J Urol. 2021;39:661–76.
Combes AD, Palma CA, Calopedos R, Wen L, Woo H, Fulham M, et al. PSMA PET-CT in the Diagnosis and Staging of Prostate Cancer. 12, Diagnostics. MDPI; 2022.
Bukavina L, Luckenbaugh AN, Hofman MS, Hope T, Kamran SC, Murphy DG, et al. Incorporating Prostate-specific Membrane Antigen Positron Emission Tomography in Management Decisions for Men with Newly Diagnosed or Biochemically Recurrent Prostate Cancer. European Urology. Elsevier B.V; 2022.
Ghai S, Eure G, Fradet V, Hyndman ME, McGrath T, Wodlinger B, et al. Assessing cancer risk on novel 29 MHz micro-ultrasound images of the prostate: creation of the micro-ultrasound protocol for prostate risk identification. J Urol. 2016;196:562–9.
Kaneko M, Lenon MSL, Storino Ramacciotti L, Medina LG, Sayegh AS, La Riva Rincon A, et al. Multiparametric ultrasound of prostate: role in prostate cancer diagnosis. 14, Therapeutic Advances in Urology. SAGE Publications Inc.; 2022.
Pavlovich CP, Cornish TC, Mullins JK, Fradin J, Mettee LZ, Connor JT, et al. High-resolution transrectal ultrasound: Pilot study of a novel technique for imaging clinically localized prostate cancer. Urologic Oncol: Semin Original Investig. 2014;32:34.e27–34.e32.
Avolio PP, Lughezzani G, Fasulo V, Maffei D, Sanchez-Salas R, Paciotti M, et al. Assessing the role of high-resolution microultrasound among naïve patients with negative multiparametric magnetic resonance imaging and a persistently high suspicion of Prostate Cancer. Eur Urol Open Sci. 2023;47:73–9.
Pavlovich CP, Hyndman ME, Eure G, Ghai S, Caumartin Y, Herget E, et al. A multi-institutional randomized controlled trial comparing first-generation transrectal high-resolution micro-ultrasound with conventional frequency transrectal ultrasound for prostate biopsy. British Journal of Urology International. 2021;126–33.
Dariane C, Ploussard G, Barret E, Beauval JB, Brureau L, Créhange G, et al. Micro-ultrasound-guided biopsies versus systematic biopsies in the detection of prostate cancer: a systematic review and meta-analysis. World J Urol. 2022;41:641–51.
Lughezzani G, Maffei D, Saita A, Paciotti M, Diana P, Buffi NM, et al. Diagnostic accuracy of microultrasound in patients with a suspicion of prostate cancer at magnetic resonance imaging: a single-institutional prospective study. Eur Urol Focus 2021;7:1019–26.
Klotz L, Lughezzani G, Maffei D, Sánchez A, Pereira JG, Staerman F, et al. Comparison of micro-ultrasound and multiparametric magnetic resonance imaging for prostate cancer: A multicenter, prospective analysis. Can Urological Assoc J. 2020;15:E11–6.
You C, Li X, Du Y, Peng L, Wang H, Zhang X, et al. The microultrasound-guided prostate biopsy in detection of prostate cancer: a systematic review and meta-analysis. J Endourol Mary Ann Liebert Inc. 2022;36:394–402.
Sountoulides P, Pyrgidis N, Polyzos SA, Mykoniatis I, Asouhidou E, Papatsoris A, et al. Micro-ultrasound-guided vs multiparametric magnetic resonance imaging-targeted biopsy in the detection of prostate cancer: a systematic review and meta-analysis. J Urol. 2021;205:1254–62.
Zhang M, Wang R, Wu Y, Jing J, Chen S, Zhang G, et al. Micro-ultrasound imaging for accuracy of diagnosis in clinically significant prostate cancer: a meta-analysis. Front Oncol. 2019;9:1368.
Avolio PP, Fasulo V, Sanchez-Salas R, Maffei D, Frego N, Lazzeri M, et al. Diagnostic accuracy of multiparametric MRI- and microultrasound-targeted biopsy in biopsy-naïve patients with a PI-RADS 5 lesion: a single-institutional study. World J Urol. 2023.
Leen E, Averkiou M, Arditi M, Burns P, Bokor D, Gauthier T, et al. Dynamic contrast enhanced ultrasound assessment of the vascular effects of novel therapeutics in early stage trials. Eur Radio. 2012;22:1442–50.
Zhao HX, Xia CX, Yin HX, Guo N, Zhu Q. The value and limitations of contrast-enhanced transrectal ultrasonography for the detection of prostate cancer. Eur J Radiol. 2013;82:e641-7.
Carpagnano FA, Eusebi L, Carriero S, Giannubilo W, Bartelli F, Guglielmi G. Prostate Cancer Ultrasound: Is Still a Valid Tool?. Curr Radiol Rep. 2021;9:7.
Frauscher F, Klauser A, Volgger H, Halpern EJ, Pallwein L, Steiner H, et al. Comparison Of Contrast Enhanced Color Doppler Targeted Biopsy With Conventional Systematic Biopsy: Impact On Prostate Cancer Detection. J Urol. 2002;167:1648–52.
Taverna G, Morandi G, Seveso M, Giusti G, Benetti A, Colombo P, et al. Colour Doppler and microbubble contrast agent ultrasonography do not improve cancer detection rate in transrectal systematic prostate biopsy sampling. BJU Int. 2011;108:1723–7.
Mannaerts CK, Engelbrecht MRW, Postema AW, van Kollenburg RAA, Hoeks CMA, Savci-Heijink CD, et al. Detection of clinically significant prostate cancer in biopsy-naïve men: direct comparison of systematic biopsy, multiparametric MRI- and contrast-ultrasound-dispersion imaging-targeted biopsy. BJU Int. 2020;126:481–93.
Cochlin DL, Ganatra RH, Griffiths DFR. Elastography in the detection of prostatic cancer. Clin Radio. 2002;57:1014–20.
Yoo JW, Koo KC, Chung BH, Lee KS. Role of the elastography strain ratio using transrectal ultrasonography in the diagnosis of prostate cancer and clinically significant prostate cancer. Sci Rep. 2022;12.
Hwang SII, Lee HJ, Lee SE, et al. Elastographic strain index in the evaluation of focal lesions detected with transrectal sonography of the prostate gland. J Ultrasound Med. 2016;35:899–904.
Zhang Y, Tang J, Li YM, Fei X, Lv FQ, He EH, et al. Differentiation of prostate cancer from benign lesions using strain index of transrectal real-time tissue elastography. Eur J Radio. 2012;81:857–62.
Zhu YC, Shan J, Zhang Y, Jiang Q, Wang YB, Deng SH, et al. Strain elastography-targeted biopsy: Does prostate volume affect prostate cancer detection? Med Sci Monit. 2019;25:8836–42.
Kanagaraju V, Ashlyin PVK, Elango N, Devanand B. Role of transrectal ultrasound elastography in the diagnosis of prostate carcinoma. J Med Ultrasound. 2020;28:173–8.
Sang L, Wang XM, Xu DY, Cai YF. Accuracy of shear wave elastography for the diagnosis of prostate cancer: A meta-analysis. Sci Rep. 2017;7.
Anbarasan T, Wei C, Bamber JC, Barr RG, Nabi G. Characterisation of prostate lesions using transrectal shear wave elastography (SWE) ultrasound imaging: A systematic review. 13, Cancers. MDPI AG; 2021. 1–15.
Xiang LH, Fang Y, Wan J, Xu G, Yao MH, Ding SS, et al. Shear-wave elastography: role in clinically significant prostate cancer with false-negative magnetic resonance imaging. Eur Radio. 2019;29:6682–9.
Fu S, Tang Y, Tan S, Zhao Y, Cui L. Diagnostic value of transrectal shear wave elastography for prostate cancer detection in peripheral zone: comparison with magnetic resonance imaging. J Endourol. 2020;34:558–66.
Jeon SS, Kim CK, Park SY, Chung JH, Kang M, Sung HH, et al. Utility of two-dimensional shear wave elastography for the prediction of prostate cancer: a preliminary study. Ultrasonography. 2023.
Dai WB, Xu J, Yu B, Chen L, Chen Y, Zhan J, et al. Correlation of stiffness of prostate cancer measured by shear wave elastography with grade group: a preliminary study. Ultrasound Med Biol. 2021;47:288–95.
Mannaerts CK, Wildeboer RR, Remmers S, Van Kollenburg RAA, Kajtazovic A, Hagemann J, et al. Multiparametric ultrasound for prostate cancer detection and localization: correlation of b-mode, shear wave elastography and contrast enhanced ultrasound with radical prostatectomy specimens. J Urol. 2019;202:1166–73.
Grey ADR, Scott R, Shah B, Acher P, Liyanage S, Pavlou M, et al. Multiparametric ultrasound versus multiparametric MRI to diagnose prostate cancer (CADMUS): a prospective, multicentre, paired-cohort, confirmatory study [Internet]. 23, 2022. Available from: www.thelancet.com/oncology
Zhang M, Tang J, Luo Y, Wang Y, Wu M, Memmott B, et al. Diagnostic performance of multiparametric transrectal ultrasound in localized prostate cancer: A comparative study with magnetic resonance imaging. J Ultrasound Med. 2019;38:1823–30.
Drudi FM, Cantisani V, Angelini F, Ciccariello M, Messineo D, Ettorre E, et al. Multiparametric MRI versus multiparametric US in the detection of prostate cancer. Anticancer Res. 2019;39:3101–10.
Mapelli P, Picchio M. Initial prostate cancer diagnosis and disease staging - The role of choline-PET-CT. 12, Nature Reviews Urology. Nature Publishing Group; 2015. 510–8.
Liu IJ, Zafar MB, Lai YH, Segall GM, Terris MK. Fluorodeoxyglucose Positron Emission Tomography Studies In Diagnosis And Staging Of Clinically Organ-Confined Prostate Cancer [Internet]. 2001. Available from: http://rsb.ingo.nih.gov/nih-image/
Cañizares G, Gonzalez-Montoro A, Freire M, Lamprou E, Barrio J, Sanchez F, et al. Pilot performance of a dedicated prostate PET suitable for diagnosis and biopsy guidance. EJNMMI Phys. 2020;7.
Caracciolo M, Castello A, Urso L, Borgia F, Ortolan N, Uccelli L, et al. The Role of [68Ga]PSMA PET/CT for Clinical Suspicion of Prostate Cancer in Patients with or without Previous Negative Biopsy: A Systematic Review. 14, Cancers. MDPI; 2022.
Eiber M, Herrmann K, Calais J, Hadaschik B, Giesel FL, Hartenbach M, et al. Prostate cancer molecular imaging standardized evaluation (PROMISE): Proposed miTNM classification for the interpretation of PSMA-ligand PET/CT. J Nucl Med. 2018;59:469–78.
Emmett L, Papa N, Buteau J, Ho B, Liu V, Roberts M, et al. The PRIMARY score: using intraprostatic 68Ga-PSMA PET/CT patterns to optimize prostate cancer diagnosis. J Nucl Med. 2022;63:1644–50.
Chandra P, Rajaian S, Krishnamurthy K, Murugasen L, Chandran G, Kumar JS, et al. Diagnostic accuracy of prebiopsy Ga-68 PSMA PET/CT in detecting primary prostate carcinomas with prostate-specific antigen <50 ng/ml. Indian. J Nucl Med. 2020;35:283–90.
Liu C, Liu T, Zhang Z, Zhang N, Du P, Yang Y, et al. 68ga-psma pet/ct combined with pet/ultrasound-guided prostate biopsy can diagnose clinically significant prostate cancer in men with previous negative biopsy results. J Nucl Med. 2020;61:1314–9.
Donato P, Morton A, Yaxley J, Ranasinghe S, Teloken PE, Kyle S, et al. 68Ga-PSMA PET/CT better characterises localised prostate cancer after MRI and transperineal prostate biopsy: Is 68Ga-PSMA PET/CT guided biopsy the future? Eur J Nucl Med Mol Imaging. 2020;47:1843–51.
Lopci E, Lughezzani G, Castello A, Saita A, Colombo P, Hurle R, et al. Prospective evaluation of 68Ga-labeled prostate-specific membrane antigen ligand positron emission tomography/computed tomography in primary prostate cancer diagnosis. Eur Urol Focus 2021;7:764–71.
Emmett L, Buteau J, Papa N, Moon D, Thompson J, Roberts MJ, et al. The additive diagnostic value of prostate-specific membrane antigen positron emission tomography computed tomography to multiparametric magnetic resonance imaging triage in the diagnosis of prostate cancer (PRIMARY): A prospective multicentre study [Formula presented]. Eur Urol. 2021;80:682–9.
Zhao Y, Simpson BS, Morka N, Freeman A, Kirkham A, Kelly D, et al. Comparison of Multiparametric Magnetic Resonance Imaging with Prostate-Specific Membrane Antigen Positron-Emission Tomography Imaging in Primary Prostate Cancer Diagnosis: A Systematic Review and Meta-Analysis. 14, Cancers. MDPI; 2022.
Manfredi C, Fernández-Pascual E, Arcaniolo D, Emberton M, Sanchez-Salas R, Artigas Guix C, et al. The Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Magnetic Resonance Imaging in Primary and Recurrent Prostate Cancer: A Systematic Review of the Literature. Eur Urology Focus. 8. Elsevier B.V; 2022. p. 942–57.
Klotz L, Andriole G, Cash H, Cooperberg M, Crawford ED, Emberton M, et al. Optimization of prostate biopsy - Micro-Ultrasound versus MRI (OPTIMUM): A 3-arm randomized controlled trial evaluating the role of 29 MHz micro-ultrasound in guiding prostate biopsy in men with clinical suspicion of prostate cancer. Contemp Clin Trials. 2022;112.
Lopci E, Lazzeri M, Colombo P, Casale P, Buffi NM, Saita A, et al. Diagnostic Performance and Clinical Impact of PSMA PET/CT versus mpMRI in Patients with a High Suspicion of Prostate Cancer and Previously Negative Biopsy: A Prospective Trial (PROSPET-BX). Urologia Internationalis. S. Karger AG; 2023.
Meissner VH, Rauscher I, Schwamborn K, Neumann J, Miller G, Weber W, et al. Radical prostatectomy without prior biopsy following multiparametric magnetic resonance imaging and prostate-specific membrane antigen positron emission tomography. Eur Urol. 2022;82:156–60.
Tokas T, Grabski B, Paul U, Bäurle L, Loch T. A 12-year follow-up of ANNA/C-TRUS image-targeted biopsies in patients suspicious for prostate cancer. World J Urol. 2018;36:699–704.
Wang X, Xie Y, Zheng X, Liu B, Chen H, Li J, et al. A prospective multi-center randomized comparative trial evaluating outcomes of transrectal ultrasound (TRUS)-guided 12-core systematic biopsy, mpMRI-targeted 12-core biopsy, and artificial intelligence ultrasound of prostate (AIUSP) 6-core targeted biopsy for prostate cancer diagnosis. World J Urol. 2022.
Secasan CC, Onchis D, Bardan R, Cumpanas A, Novacescu D, Botoca C, et al. Artificial intelligence system for predicting prostate cancer lesions from shear wave elastography measurements. Curr Oncol. 2022;29:4212–23.
Holzgreve A, Unterrainer M, Calais J, Adams T, Oprea-Lager DE, Goffin K, et al. Is PSMA PET/CT cost-effective for the primary staging in prostate cancer? First results for European countries and the USA based on the proPSMA trial. Eur J Nucl Med Mol Imaging. 2023 Jul;
This research received no external funding
The authors have no competing interests.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Ditonno, F., Franco, A., Manfredi, C. et al. Novel non-MRI imaging techniques for primary diagnosis of prostate cancer: micro-ultrasound, contrast-enhanced ultrasound, elastography, multiparametric ultrasound, and PSMA PET/CT. Prostate Cancer Prostatic Dis (2023). https://doi.org/10.1038/s41391-023-00708-9
This article is cited by
Prostate Cancer and Prostatic Diseases (2023)
Prostate Cancer in Transgender Women: Epidemiology, Clinical Characteristics, and Management Challenges
Current Oncology Reports (2023)